Pacific Biosciences of California vs 10x Genomics
PACB and TXG side by side, both in laboratory apparatus and analytical, optical, measuring, and controlling instruments. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How PACB and TXG compare
10x Genomics is the larger company, worth 11 times as much as Pacific Biosciences of California ($9.1B against $810M).
Pacific Biosciences of California grew revenue faster over the last twelve months (2.0% versus −4.3% for 10x Genomics).
10x Genomics keeps more of each dollar of sales as profit, with a net margin of −12.2% compared with −82.5% at Pacific Biosciences of California.
10x Genomics scores higher on the StockData Score (9 against 3 for Pacific Biosciences of California), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | PACB | TXG |
|---|---|---|
| Size and price | ||
| Market cap | $810M | $9.1B |
| Share price | $2.60 | $70.11 |
| Change, 1 year | 29.6% | 443% |
| Change, 5 years | −91.1% | −60.6% |
| Beta (5Y) | 2.23 | 2.05 |
| Employees | 485 | 1,178 |
| StockData Score | ||
| Total score | 3 | 9 (better) |
| Valuation score | 0 | 0 |
| Growth score | 1 | 2 (better) |
| Performance score | 1 | 1 |
| Health score | 1 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 5.1× (better) | 14.8× |
| P/B | – | 11.1× |
| P/FCF | – | 75.2× |
| FCF yield | −15.2% | 1.3% (better) |
| Fair value | – | $26.97 |
| Margin of safety | – | −160% |
| Growth | ||
| Revenue growth (TTM) | 2.0% (better) | −4.3% |
| Revenue growth, 5Y average | 15.2% | 16.6% (better) |
| Profitability | ||
| Gross margin | 36.4% | 70.0% (better) |
| Operating margin | −83.5% | −14.3% (better) |
| Net margin | −82.5% | −12.2% (better) |
| FCF margin | −77.5% | 19.7% (better) |
| Return on equity | −929% | −9.4% (better) |
| Return on invested capital | – | −23.3% |
| Financial health | ||
| Debt / equity | – | 0.00 |
| Interest coverage | −18.2× | – |
| Current ratio | 4.92 | 5.69 (better) |
| Altman Z-score | −4.44 | 25.67 (better) |
| Piotroski F-score | 4 | 6 (better) |
| Dividends and buybacks | ||
| Dividend yield | 0.00% | – |
| Years of dividend growth | 0 | – |
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 61.5% | 98.7% |
| Held by insiders | 4.4% | 4.3% |
| Insider net buying, 12 months | −$1.3M (better) | −$16.9M |
| Superinvestors holding | 1 | 1 |
| Short interest, % of float | 15.9% | 12.3% |
Go deeper
- PACB stock overview
- PACB income statement
- PACB valuation and score
- TXG stock overview
- TXG income statement
- TXG valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.